ScienceDaily
A new class of drugs could prevent resistant COVID-19 variants, study finds
The constant evolution of new COVID-19 variants makes it critical for clinicians to have multiple therapies in their arsenal for treating drug-resistant infections. Researchers have now discovered that a new class of oral drugs that acts directly on human cells can inhibit a diverse range of pathogenic SARS-CoV-2 strains.
Read More
ScienceDaily
First nasal monoclonal antibody treatment for COVID-19 shows promise for treating virus, other diseases: In a pilot trial and clinical sample-based investigations, the drug Foralumab decreased inflammatory markers in patients with COVID-19
A pilot trial tested the nasal administration of the drug Foralumab, an anti-CD3 monoclonal antibody. Investigators found evidence that the drug dampened the inflammatory T cell response and decreased lung inflammation in patients with COVID-19. Further analysis showed the same gene expression modulation in patients with multiple sclerosis, who experienced decreased brain inflammation, suggesting that Foralumab could be used to treat other diseases.
Read More